Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Novartis AG made an official statement today, saying that it reached an agreement over the acquisition of the cancer-drug unit of GlaxoSmithKline Plc in a 16-billion-dollar deal. The two companies will also form a joint venture by combining their consumer-health divisions, which sell medicines that dont require a prescription.

According to the companys statement, Novartis plans to sell its animal-health division to Eli Lilly & Co. in a deal estimated to 5.4 billion dollars. It also said that its vaccines unit, excluding the flu operations, will be acquired by GlaxoSmithKline at the price of 7.1 billion dollars.

These deals are part of the plan for reorganization of the company, which has been started in 2013 and is a part of a long-term strategy to bet on higher-margin products, while getting rid of lower-margin units.

As reported by the Wall Street Journal, Mr. Joe Jimenez, the current Chief Executive Officer of Novartis AG, said: “The transactions mark a transformational moment for Novartis.” Part of Mr. Jimenez statement was also cited by Bloomberg: “You have to be No. 1, No. 2 or No. 3 in your segment. This was so critical we talked with virtually everyone.”

According to the information provided by the company, the joint venture that is to be formed by Novartis and GlaxoSmithKline is expected to generate a revenue that amounts to about 6.5 billion pounds (10.9 billion dollars). The major equity stake will be held by Glaxo. As reported by Bloomberg, the Glaxos CEO – Andrew Witty commented on this step: “Opportunities to build greater scale and combine high-quality assets in vaccines and consumer health care are scarce. With this transaction, we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders.”

Novartis AG currently focuses on four specific segments that are expected to generate about 70% of its total sales. It is to bet on the units that are responsible for respiratory, HIV, consumer health products and vaccines. The companys idea is to expand its reach in vaccines, by consolidating its positions and making larger investments in the development of about 20 new vaccines.

Novartis AG was 2.34% up to trade at 76.45 Swiss francs by 10:20 GMT, marking a one-year change of +13.6%.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Johnson & Johnson announces “exceptional” growth in pharmaceuticals businessJohnson & Johnson announces “exceptional” growth in pharmaceuticals business Johnson & Johnson announced “exceptional” growth in its pharmaceuticals business thanks to the rewards from a series of successful drug launches. Prescription medicines has proved itself to be the strongest part of the companys portfolio […]
  • Natural gas extends gains on Midwest heatNatural gas extends gains on Midwest heat Natural gas futures rose for a third day in four as weather forecasts continued to point at above-average temperatures across the U.S. Midwest, boosting demand for the power plant fuel.On the New York Mercantile Exchange, natural gas for […]
  • Natural gas trading outlook: futures climb ahead of the EIA reportNatural gas trading outlook: futures climb ahead of the EIA report Natural gas futures were higher during early trade in Europe today, ahead of the US weekly inventories levels report. Analysts suggest another sizable gain for nat gas stocks, while weather patterns project more moderate weather for the US in […]
  • Gold rises on Fed stimulus uncertainty, Syria concernGold rises on Fed stimulus uncertainty, Syria concern Gold rose for a fourth day following two days of surprisingly disappointing U.S. economic data, which dampened speculations that the Federal Reserve will start decelerating its $85 billion bond purchasing program in September. Some safe haven […]
  • Forex Market: USD/CAD daily trading outlookForex Market: USD/CAD daily trading outlook Yesterday’s trade saw USD/CAD within the range of 1.3879-1.4017. The pair closed at 1.3918, inching down 0.05% on a daily basis. It has been the 12th drop in the past 28 trading days. In addition, the daily high has been the highest level […]
  • USD/INR trades near two-month trough on dollar selling, inflowsUSD/INR trades near two-month trough on dollar selling, inflows Key pointsUSD/INR at fresh two-month low Dollar selling, debt and equity inflows boost Rupee US ISM Manufacturing PMI data in focusIndia's Rupee advanced to highs unseen since early May against the US Dollar on […]